RT Journal Article
T1 Impact of Biological Agents on Postsurgical Complications in Inflammatory Bowel Disease: A Multicentre Study of Geteccu.
A1 García, María José
A1 Rivero, Montserrat
A1 Miranda-Bautista, José
A1 Bastón-Rey, Iria
A1 Mesonero, Francisco
A1 Leo-Carnerero, Eduardo
A1 Casas-Deza, Diego
A1 Cagigas Fernández, Carmen
A1 Martin-Cardona, Albert
A1 El Hajra, Ismael
A1 Hernández-Aretxabaleta, Nerea
A1 Pérez-Martínez, Isabel
A1 Fuentes-Valenzuela, Esteban
A1 Jiménez, Nuria
A1 Rubín de Célix, Cristina
A1 Gutiérrez, Ana
A1 Suárez Ferrer, Cristina
A1 Huguet, José María
A1 Fernández-Clotet, Agnes
A1 González-Vivó, María
A1 Del Val, Blanca
A1 Castro-Poceiro, Jesús
A1 Melcarne, Luigi
A1 Dueñas, Carmen
A1 Izquierdo, Marta
A1 Monfort, David
A1 Bouhmidi, Abdel
A1 Ramírez De la Piscina, Patricia
A1 Romero, Eva
A1 Molina, Gema
A1 Zorrilla, Jaime
A1 Calvino-Suárez, Cristina
A1 Sánchez, Eugenia
A1 Nuñez, Andrea
A1 Sierra, Olivia
A1 Castro, Beatriz
A1 Zabana, Yamile
A1 González-Partida, Irene
A1 De la Maza, Saioa
A1 Castaño, Andrés
A1 Nájera-Muñoz, Rodrigo
A1 Sánchez-Guillén, Luis
A1 Riat Castro, Micaela
A1 Rueda, José Luis
A1 Benítez, José Manuel
A1 Delgado-Guillena, Pedro
A1 Tardillo, Carlos
A1 Peña, Elena
A1 Frago-Larramona, Santiago
A1 Rodríguez-Grau, María Carmen
A1 Plaza, Rocío
A1 Pérez-Galindo, Pablo
A1 Martínez-Cadilla, Jesús
A1 Menchén, Luis
A1 Barreiro-De Acosta, Manuel
A1 Sánchez-Aldehuelo, Rubén
A1 De la Cruz, María Dolores
A1 Lamuela, Luis Javier
A1 Marín, Ignacio
A1 Nieto-García, Laura
A1 López-San Román, Antonio
A1 Herrera, José Manuel
A1 Chaparro, María
A1 Gisbert, Javier P
A1 On Behalf Of The Young Group Of Geteccu, 
K1 Crohn’s disease
K1 anti-TNF
K1 inflammatory bowel disease
K1 postoperative complications
K1 preoperative therapy
K1 surgery
K1 ulcerative colitis
K1 ustekinumab
K1 vedolizumab
AB The impact of biologics on the risk of postoperative complications (PC) in inflammatory bowel disease (IBD) is still an ongoing debate. This lack of evidence is more relevant for ustekinumab and vedolizumab. To evaluate the impact of biologics on the risk of PC. A retrospective study was performed in 37 centres. Patients treated with biologics within 12 weeks before surgery were considered "exposed". The impact of the exposure on the risk of 30-day PC and the risk of infections was assessed by logistic regression and propensity score-matched analysis. A total of 1535 surgeries were performed on 1370 patients. Of them, 711 surgeries were conducted in the exposed cohort (584 anti-TNF, 58 vedolizumab and 69 ustekinumab). In the multivariate analysis, male gender (OR: 1.5; 95% CI: 1.2-2.0), urgent surgery (OR: 1.6; 95% CI: 1.2-2.2), laparotomy approach (OR: 1.5; 95% CI: 1.1-1.9) and severe anaemia (OR: 1.8; 95% CI: 1.3-2.6) had higher risk of PC, while academic hospitals had significantly lower risk. Exposure to biologics (either anti-TNF, vedolizumab or ustekinumab) did not increase the risk of PC (OR: 1.2; 95% CI: 0.97-1.58), although it could be a risk factor for postoperative infections (OR 1.5; 95% CI: 1.03-2.27). Preoperative administration of biologics does not seem to be a risk factor for overall PC, although it may be so for postoperative infections.
SN 2077-0383
YR 2021
FD 2021-09-26
LK https://hdl.handle.net/10668/26084
UL https://hdl.handle.net/10668/26084
LA en
DS RISalud
RD Apr 17, 2025